Epicept press release
October 26, 2009New Data Supports Pharmacoeconomic Benefits of Ceplene(R) TARRYTOWN, N.Y., Oct 26, 2009 (BUSINESS WIRE) — Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene(R) (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission. These data are being presented in two separate poster presentations on October 25 and 27, 2009 in Paris, France at the Twelfth Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Researchers from Applied Healthcare Resource Management Inc. engaged by EpiCept analyzed data from the pivotal Phase III clinical trial for Ceplene(R) to determine the incremental cost effectiveness of Ceplene(R) with low-dose interleukin-2 (IL-2) versus current standard of care for remission maintenance of AML patients in first complete remission. Read More